There are going to be some busy pharmaceutical companies over the next few weeks as the deadline Facebook set for disallowing companies on its social network from disabling the comments section on their profiles approaches.
Many pharma brands have got around the thorny problem of whether or not to allow comments by simply disabling the facility on their Facebook profiles, but that option will no longer be available from August 15. After this date, they have the option of pulling their profiles down or opening up the comments function: which many will see as being thrust between a rock and a hard place.
As the FDA continues to prevaricate around its social media guidelines, pharma companies are going to have to use their own common sense and initiative to get their acts together in short order - and they will need a lot of support from their PR and communications agencies to avoid getting themselves in hot water with the regulator.
I'd be interested in knowing what the PRWeek community thinks about this thorny problem and how in-house teams are, or would, react or how agencies would advise their clients to react to the new conditions so communications is seamless, effective – and legal. Is this ultimately going to be good or bad for pharmaceutical companies?
You can append comments to this article, or email me directly if you prefer to remain anonymous.